Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

Representative before the EPO

Technology company logo thumb
no operation time available
2 offices
Technology Company

Representative before the EPO

Technology company logo thumb
no operation time available
2 offices
Technology Company

We have observed 9 EP applications Philippe Bouvet has served for within the last five+ years. (We consider all applications which have an EP A1 or A2 publication dated after April 22, 2013). Please note, that we only count EP applications, in which the name of the patent attorney is explicitly mentioned as representative. These EP applications are:

EP12704842

SINGLE NUCLEOTIDE POLYMORPHISMS IN THE PROMOTER OF VEGFA GENE AND THEIR USE AS PREDICTIVE MARKERS FOR ANTI-VEGF TREATMENTS

IPC classification:
C12Q 1/68
Applicant:
Sanofi, S.A.
Agent:
Philippe Bouvet, Sanofi, S.A.
Agent:
Philippe Bouvet, Sanofi
Status:
The patent has been granted
EP12706541

METHOD OF PRODUCTION OF SIALYLATED ANTIBODIES

IPC classification:
C07K 16/18
Applicant:
Sanofi, S.A.
Agent:
Philippe Bouvet, Sanofi, S.A.
Agent:
Philippe Bouvet, Sanofi
Status:
GRANT OF PATENT INTENDED
EP12717129

COMPOSITION COMPRISING AFLIBERCEPT, FOLINIC ACID, 5-FLUOROURACIL (5-FU) AND IRINOCETAN (FOLFIRI)

IPC classification:
A61K 31/4745, A61K 31/505, A61K 31/519, A61K 38/17, A61P 35/00
Applicant:
Sanofi, S.A.
Agent:
Philippe Bouvet, Sanofi, S.A.
Agent:
Philippe Bouvet, Sanofi
Status:
PATENT GRANTED
EP12769684

COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND METHODS OF USING SAME

IPC classification:
A61K 31/42, A61K 31/519, A61K 31/655, A61K 39/395, A61K 45/06, C07K 16/28
Applicant:
Sanofi, S.A.
Applicant:
Regeneron Pharmaceuticals Inc
Agent:
Philippe Bouvet, Sanofi, S.A.
Agent:
BĂ©atrice Holtz, Cabinet Lavoix
Agent:
Philippe Bouvet, Sanofi
Status:
The patent has been granted
EP13745404

ARTICLE OF MANUFACTURE COMPRISING AFLIBERCEPT OR ZIV-AFLIBERCEPT

IPC classification:
A61K 9/00, A61K 31/4745, A61K 31/513, A61K 31/519, A61K 38/18, A61P 35/00
Applicant:
Sanofi, S.A.
Agent:
Philippe Bouvet, Sanofi, S.A.
Agent:
Philippe Bouvet, Sanofi
Status:
EXAMINATION IN PROGRESS
EP13794894

ANTI-CEACAM5 ANTIBODIES AND USES THEREOF

IPC classification:
A61K 39/395, A61P 35/00, C07K 16/30
Applicant:
Sanofi, S.A.
Agent:
Philippe Bouvet, Sanofi
Status:
PATENT GRANTED
EP15738625

METHOD FOR PREDICTING THE OUTCOME OF A TREATMENT WITH AFLIBERCEPT OF A PATIENT SUSPECTED TO SUFFER FROM A CANCER

IPC classification:
G01N 33/574
Applicant:
Sanofi, S.A.
Agent:
Philippe Bouvet, Sanofi
Status:
EXAMINATION REQUESTED
EP17157890

ANTI-CEACAM5 ANTIBODIES AND USES THEREOF

IPC classification:
A61K 39/395, A61P 35/00, C07K 16/30
Applicant:
Sanofi, S.A.
Agent:
Philippe Bouvet, Sanofi
Status:
The application has been published
EP16704440

STABLE LIQUID FORMULATION FOR MONOCLONAL ANTIBODIES

IPC classification:
A61K 39/395, C07K 16/24
Applicant:
Sanofi, S.A.
Agent:
Philippe Bouvet, Sanofi
Status:
Request for examination was made

Please Sign in to use this feature